Figure 1
![Figure 1. Cumulative incidence for first SRE by bisphosphonate (ZOL vs CLO). (A) Patients who achieved a VGPR or less posttransplant (P = .048); PR (hazard ratio 0.74 [HR]; 95% confidence interval [CI], 0.52-1.05); VGPR (HR, 0.87; 95% CI, 0.60-1.27). (B) Patients who achieved a CR posttransplant (HR, 1.05, 95% CI, 0.82-1.35; P = .83).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/122/17/10.1182_blood-2013-04-498139/4/2974f1.jpeg?Expires=1722775274&Signature=NenzPragoZpc4z0inSdUkCg1XOnRQY3wVb9KdJMqvBD-nR~pBz6jXfWrRw8jD3zxHmKaKOUZ6jgwKCGPqtfxYU2V2LXsYvdFJTztXeO6M9Ia8A8zwrlrWi6s2bgFE8VmBxykdVt6FEVSJXvFuK9AVCp5wX3qj~XqCP0tX~B2PTxevLtspYuMhnQFN6sjz6XCl15DyGtCUD8qS8-3qJ1d8-1e3fGlt9qtUOnwrgp~-RAh~zG0NzZ6OmdENEIsXbnJtVxJRFyqOYhb~gyPsFdO9zWhGs7wgG8W83uOiHCEtdRIQlCDkOxtB7YuQXBMcovE8kVOZQBrWw5VXX-3zmc~xA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Cumulative incidence for first SRE by bisphosphonate (ZOL vs CLO). (A) Patients who achieved a VGPR or less posttransplant (P = .048); PR (hazard ratio 0.74 [HR]; 95% confidence interval [CI], 0.52-1.05); VGPR (HR, 0.87; 95% CI, 0.60-1.27). (B) Patients who achieved a CR posttransplant (HR, 1.05, 95% CI, 0.82-1.35; P = .83).
